- Home
- AGIO vs HRMY Comparison
AGIO vs HRMY Comparison
Compare AGIO & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- HRMY
- Stock Information
- Founded
- AGIO 2007
- HRMY 2017
- Country
- AGIO United States
- HRMY United States
- Employees
- AGIO N/A
- HRMY N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- AGIO Health Care
- HRMY Health Care
- Exchange
- AGIO Nasdaq
- HRMY Nasdaq
- Market Cap
- AGIO 2.0B
- HRMY 2.0B
- IPO Year
- AGIO 2013
- HRMY 2020
- Fundamental
- Price
- AGIO $30.28
- HRMY $33.19
- Analyst Decision
- AGIO Buy
- HRMY Strong Buy
- Analyst Count
- AGIO 8
- HRMY 8
- Target Price
- AGIO $56.57
- HRMY $54.00
- AVG Volume (30 Days)
- AGIO 637.9K
- HRMY 692.3K
- Earning Date
- AGIO 05-01-2025
- HRMY 04-29-2025
- Dividend Yield
- AGIO N/A
- HRMY N/A
- EPS Growth
- AGIO N/A
- HRMY 17.84
- EPS
- AGIO 11.64
- HRMY 2.51
- Revenue
- AGIO $36,498,000.00
- HRMY $714,734,000.00
- Revenue This Year
- AGIO $50.61
- HRMY $20.92
- Revenue Next Year
- AGIO $223.79
- HRMY $18.83
- P/E Ratio
- AGIO $2.60
- HRMY $13.22
- Revenue Growth
- AGIO 36.07
- HRMY 22.80
- 52 Week Low
- AGIO $27.14
- HRMY $28.14
- 52 Week High
- AGIO $62.58
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- AGIO 39.54
- HRMY 43.39
- Support Level
- AGIO $30.00
- HRMY $32.85
- Resistance Level
- AGIO $32.90
- HRMY $33.77
- Average True Range (ATR)
- AGIO 1.22
- HRMY 1.21
- MACD
- AGIO -0.08
- HRMY 0.03
- Stochastic Oscillator
- AGIO 9.12
- HRMY 28.66
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.